OBJECTIVES: Perinatal single-dose nevirapine (sdNVP) selects for resistance mutations. The objective of this trial was to compare two maternal sdNVP-sparing regimens with standard zidovudine (ZDV)/sdNVP prophylaxis. DESIGN: PHPT-5 was a randomized, partially double-blind placebo-controlled, noninferiority trial in Thailand (NCT00409591). Study participants were women with CD4 of at least 250 cells/mul and their infants. METHODS: All women received ZDV from 28 weeks' gestation and their newborn infants for one week. Women were also randomized to receive NVP-NVP (reference): maternal intrapartum sdNVP with a 7-day 'tail' of ZDV along with lamivudine, and infant NVP (one dose immediately, another 48 h later); infant-only NVP: maternal placebos...
Single-dose nevirapine (sdNVP)—which prevents mother-to-child transmission of HIV—selects non-nucleo...
Background & objectives: Resistance to nevirapine (NVP) has been described with single dose prev...
Introduction: Infants born to women living with HIV initiating combination antiretroviral therapy (c...
OBJECTIVES: Perinatal single-dose nevirapine (sdNVP) selects for resistance mutations. The objective...
Background. Intrapartum single-dose (SD) nevirapine (NVP) reduces perinatal transmission of human im...
CONTEXT: A 2-dose intrapartum/newborn nevirapine regimen reduced perinatal human immunodeficiency vi...
BACKGROUND: The optimal duration of zidovudine administration to prevent perinatal transmission of h...
To determine the efficacy and safety of 2 inexpensive and easily deliverable antiretroviral (ARV) re...
To determine the efficacy and safety of 2 inexpensive and easily deliverable antiretroviral (ARV) re...
BACKGROUND: A single dose of nevirapine during labor reduces perinatal transmission of human immunod...
HIV transmissions to investigate the preventive role of various antiretroviral treatments intervent...
Administration of potent antiretroviral combination therapy in the second and third trimester of pre...
BACKGROUND: Intrapartum single-dose nevirapine plus third trimester maternal and infant zidovudine a...
Background. Intrapartum single-dose (SD) nevirapine (NVP) reduces perinatal transmission of human im...
Background. Intrapartum single-dose nevirapine plus third trimester maternal and infant zidovudine a...
Single-dose nevirapine (sdNVP)—which prevents mother-to-child transmission of HIV—selects non-nucleo...
Background & objectives: Resistance to nevirapine (NVP) has been described with single dose prev...
Introduction: Infants born to women living with HIV initiating combination antiretroviral therapy (c...
OBJECTIVES: Perinatal single-dose nevirapine (sdNVP) selects for resistance mutations. The objective...
Background. Intrapartum single-dose (SD) nevirapine (NVP) reduces perinatal transmission of human im...
CONTEXT: A 2-dose intrapartum/newborn nevirapine regimen reduced perinatal human immunodeficiency vi...
BACKGROUND: The optimal duration of zidovudine administration to prevent perinatal transmission of h...
To determine the efficacy and safety of 2 inexpensive and easily deliverable antiretroviral (ARV) re...
To determine the efficacy and safety of 2 inexpensive and easily deliverable antiretroviral (ARV) re...
BACKGROUND: A single dose of nevirapine during labor reduces perinatal transmission of human immunod...
HIV transmissions to investigate the preventive role of various antiretroviral treatments intervent...
Administration of potent antiretroviral combination therapy in the second and third trimester of pre...
BACKGROUND: Intrapartum single-dose nevirapine plus third trimester maternal and infant zidovudine a...
Background. Intrapartum single-dose (SD) nevirapine (NVP) reduces perinatal transmission of human im...
Background. Intrapartum single-dose nevirapine plus third trimester maternal and infant zidovudine a...
Single-dose nevirapine (sdNVP)—which prevents mother-to-child transmission of HIV—selects non-nucleo...
Background & objectives: Resistance to nevirapine (NVP) has been described with single dose prev...
Introduction: Infants born to women living with HIV initiating combination antiretroviral therapy (c...